鲁平病疫苗市场规模、份额和成长分析：按疫苗类型、最终用户、通路、配方和地区划分－2026-2033年产业预测

2024年全球环状肝炎疫苗市值为47亿美元，预计2025年将成长至50.6亿美元，2033年将成长至91.6亿美元。预测期（2026-2033年）的复合年增长率预计为7.7%。

全球环状脑炎疫苗市场的主要驱动力是持续存在的蜱传病毒性脑炎风险，这种风险会影响绵羊和山羊，促使农民和公共卫生机构加强疫苗接种力度。该市场涵盖旨在预防神经系统疾病的兽用生技药品，这些疾病会降低牲畜生产力并威胁农村经济。近期进展包括灭活疫苗的改进和在高风险地区加强分发策略，从而提高了公众意识和监测。监管协调和对兽医基础设施的投资进一步降低了疫苗推广的门槛，并促进了广泛的免疫接种活动。此外，最尖端科技透过简化候选疫苗的发现、测试物流和预测分析，提高了疫苗研发效率，从而激发了私营部门的兴趣并增强了市场的永续性。

全球环状病毒病疫苗市场驱动因素

全球羊环状绦虫病疫苗市场的主要驱动因素是牲畜（尤其是绵羊）羊环状绦虫病发病率的不断上升，这提高了农民和兽医专业人员的认识。随着人们对该疾病对牲畜生产力和健康造成的经济影响的认识不断加深，对有效疫苗的需求也不断增长。此外，疫苗技术和配方的进步提高了羊环状绦虫病疫苗的有效性和安全性，进一步加速了疫苗的推广应用。同时，政府对农业领域疾病预防的支持和资金投入也显着促进了该市场的成长，并确保了牲畜健康管理采取积极主动的方式。

全球循环疾病疫苗市场的限制因素

全球环状绦虫病疫苗市场的主要阻碍因素是畜牧养殖户和兽医对环状绦虫病的认识和了解有限。这种知识匮乏会导致疫苗接种率低下，因为许多相关人员低估了疾病的影响或未能认识到接种疫苗的益处。此外，预算限制和其它卫生优先事项可能导致畜牧养殖户不愿投资疫苗，尤其是在他们认为疾病发生率较低的地区。因此，这种情况阻碍了市场成长，并影响了动物健康疾病控制策略的整体有效性。

全球循环疾病疫苗市场趋势

全球循环疾病疫苗市场正经历着向「同一健康」一体化倡议的显着转变，该倡议强调兽医服务、公共卫生机构、野生动物管理者和农业社区之间的跨部门合作。这种合作模式共用协调的监测活动和共享的风险评估，促进高风险地区进行有针对性的免疫宣传活动，从而重新定义了疫苗策略。透过建立信任和共用资源，这些努力使兽医实践与通用感染疾病控制和公共卫生优先事项保持一致。动物健康、人类健康和生态学因素的整合正在加速疫苗计画的部署，推动永续的控制工作，并提高相关人员在循环疾病管理中的参与。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球狼疮抗病毒疫苗市场规模：按疫苗类型和复合年增长率划分（2026-2033 年）

• 灭活疫苗
  • 所有病毒疫苗
  • 次单位疫苗
• 减毒活病毒疫苗

全球狼疮性肺炎疫苗市场规模：按最终用户和复合年增长率划分（2026-2033 年）

• 动物医院
• 研究机构

全球狼疮抗病毒疫苗市场规模：按分销管道和复合年增长率划分（2026-2033 年）

• 直销
• 线上零售
• 批发商

全球狼疮抗病毒疫苗市场规模：按剂型和复合年增长率划分（2026-2033 年）

• 注射药物
• 口服疫苗

全球鲁平病疫苗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Zoetis
• Merck Animal Health
• Ceva Sante Animale
• Boehringer Ingelheim Animal Health
• Elanco Animal Health
• Neogen Corporation
• Virbac
• Hipra
• Synlogic
• Aggressopet
• Vetoquinol
• IDEXX Laboratories
• Pharmgate
• Kemin Industries
• AgriLabs
• Biovac
• Global Animal Products
• Alltech
• Vetoquinol
• Wuxi Biologics

结论与建议

Global Louping Ill Vaccines Market size was valued at USD 4.7 Billion in 2024 and is poised to grow from USD 5.06 Billion in 2025 to USD 9.16 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global louping ill vaccines market is primarily driven by the ongoing risk of tick-borne viral encephalitis affecting sheep and goats, prompting a focus on vaccination efforts by farmers and public health entities. This market encompasses veterinary biologics aimed at preventing neurological diseases that can lower flock productivity and jeopardize rural economies. Historical advancements have witnessed the evolution of inactivated vaccines and enhanced distribution strategies in high-risk regions, achieving greater awareness and surveillance. Regulatory harmonization and investments in veterinary infrastructure further lower adoption barriers, facilitating widespread immunization efforts. Additionally, cutting-edge developments in AI promote efficiency in vaccine development by streamlining candidate discovery, trial logistics, and predictive analytics, fostering interest from the private sector and enhancing market sustainability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Louping Ill Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Louping Ill Vaccines Market Segments Analysis

Global louping ill vaccines market is segmented by vaccine type, end user, distribution channel, formulation and region. Based on vaccine type, the market is segmented into Inactivated Vaccines and Live Attenuated Vaccines. Based on end user, the market is segmented into Veterinary Clinics and Research Institutions. Based on distribution channel, the market is segmented into Direct Sales, Online Retail and Distributors. Based on formulation, the market is segmented into Injectable Formulations and Oral Vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Louping Ill Vaccines Market

A key market driver for the Global Louping Ill Vaccines Market is the increasing incidence of louping ill disease in livestock, particularly sheep, which has raised awareness among farmers and veterinary professionals. The growing understanding of the disease's economic impact on livestock productivity and health is driving the demand for effective vaccination solutions. Additionally, advancements in vaccine technology and formulation are enhancing the efficacy and safety profiles of louping ill vaccines, further boosting their adoption. Furthermore, supportive government initiatives and funding aimed at disease prevention in agriculture are contributing significantly to the growth of this market, ensuring a proactive approach to livestock health management.

Restraints in the Global Louping Ill Vaccines Market

A significant restraint in the global louping ill vaccines market is the limited awareness and understanding of louping ill disease among livestock producers and veterinarians. This lack of knowledge can lead to lower vaccination rates, as many stakeholders may underestimate the disease's impact or fail to recognize the benefits of vaccination. Furthermore, budget constraints and competing health priorities may deter livestock owners from investing in vaccines, especially in regions where the disease is perceived as less prevalent. Consequently, this situation hinders market growth and affects the overall efficacy of disease management strategies in animal health.

Market Trends of the Global Louping Ill Vaccines Market

The Global Louping Ill Vaccines market is witnessing a significant trend towards integrated One Health initiatives that emphasize cross-sector collaboration among veterinary services, public health authorities, wildlife managers, and farming communities. This collaborative approach is redefining vaccination strategies, as coordinated surveillance and shared risk assessments facilitate targeted immunization campaigns in high-risk areas. By fostering trust and resource-sharing, these initiatives align veterinary practices with zoonotic disease management and public health priorities. The integration of animal health with human health and ecological factors is enhancing the adoption of vaccine programs, driving sustainable control efforts, and increasing stakeholder engagement in managing louping ill.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Louping Ill Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Inactivated Vaccines
  • Whole Virus Vaccines
  • Subunit Vaccines
• Live Attenuated Vaccines

Global Louping Ill Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Veterinary Clinics
• Research Institutions

Global Louping Ill Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Online Retail
• Distributors

Global Louping Ill Vaccines Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Injectable Formulations
• Oral Vaccines

Global Louping Ill Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, End User, Distribution Channel, Formulation)
  • US
  • Canada
• Europe (Vaccine Type, End User, Distribution Channel, Formulation)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, End User, Distribution Channel, Formulation)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, End User, Distribution Channel, Formulation)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, End User, Distribution Channel, Formulation)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hipra
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlogic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aggressopet
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmgate
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AgriLabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Animal Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations